TAM
BBIO icon

Tocqueville Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Tocqueville Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Buy
19,650
+825
+4% +$57.8K 0.02% 337
2026
Q1 		$1.4M Buy
18,825
+50
+0.3% +$3.62K 0.02% 323
2025
Q4 		$1.44M Hold
18,775
– – 0.02% 337
2025
Q3 		$975K Buy
18,775
+25
+0.1% +$1.22K 0.01% 367
2025
Q2 		$810K Sell
18,750
-300
-2% -$10.9K 0.01% 379
2025
Q1 		$659K Buy
19,050
+75
+0.4% +$2.53K 0.01% 381
2024
Q4 		$521K Buy
18,975
+1,275
+7% +$33K 0.01% 423
2024
Q3 		$451K Buy
17,700
+2,500
+16% +$65.6K 0.01% 420
2024
Q2 		$385K Buy
15,200
+2,500
+20% +$68.4K 0.01% 434
2024
Q1 		$393K Sell
12,700
-700
-5% -$23.8K 0.01% 435
2023
Q4 		$541K Sell
13,400
-800
-6% -$24K 0.01% 387
2023
Q3 		$374K Sell
14,200
-5,050
-26% -$143K 0.01% 424
2023
Q2 		$331K Sell
19,250
-2,800
-13% -$42.1K 0.01% 450
2023
Q1 		$366K Buy
+22,050
New +$257K 0.01% 436

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Tocqueville Asset Management's BBIO Position: Q2 2026 in Review

Tocqueville Asset Management increased its BridgeBio Pharma (BBIO) stake by 4.4% in Q2 2026, buying an estimated $57.8K and bringing the position to 19,650 shares worth $1.46M. The position accounts for 0.02% of the portfolio, ranked #337.

Tocqueville Asset Management first reported a position in BBIO in Q1 2023 and has held it in 14 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Tocqueville Asset Management held 19,650 shares of BridgeBio Pharma worth $1.46M as of Q2 2026.
  • Tocqueville Asset Management bought 825 BridgeBio Pharma shares in Q2 2026, an estimated $57.8K.
  • BridgeBio Pharma made up 0.02% of Tocqueville Asset Management's portfolio in Q2 2026, its #337 holding.
  • Tocqueville Asset Management first reported a position in BridgeBio Pharma in Q1 2023 and has held it in 14 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Tocqueville Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.